Long-term acceptability of perindopril: European multicenter trial on 856 patients

Degaute, Jean-Paul; Leeman, Marc; Desché, P.

doi:10.1016/0002-9343(92)90154-4

Cited by 17 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overall withdrawal rate because of side-effects was low (7.9%), and the most common side-effects were cough (2.2%), digestive problems (0.8%), skin rash (Oh%), sexual problems (0.4%), angina, myocardial infarction or stroke (1.03%), taste disturbance (0.2%) and miscellaneous symptoms (1.7%). Full details of this study have been reported elsewhere in the literature (Degaute et al 1992).…”

Section: Long-term Perindopril Acceptabilitymentioning

confidence: 99%

Angiotensin‐converting Enzyme Inhibition as First‐line Treatment for Hypertension

Thurston

1992

Clin Exp Pharma Physio

View full text Add to dashboard Cite

1. Perindopril (4 mg) was compared with atenolol (50 mg), captopril (25 mg b.d.) or a diuretic (hydrochlorothiazide 50 mg and amiloride 5 mg) in three studies involving a total of 503 hypertensive patients with a diastolic blood pressure (DBP) of 95-125 mmHg.2. A 4 week single-blind placebo period preceded 12 weeks of active treatment. Dose titration was at weeks 4 and 8 if supine DBP >90 mmHg. The dose was doubled and if necessary a diuretic was added in the atenolol or captopril comparisons, and atenolol was added in the diuretic study.3. The fall in supine blood pressure (BP) was 27/ 17 mmHg with perindopril and 21 / 16 mmHg for atenolol. Monotherapy controlled 55% of patients on perindopril and 48% on atenolol, increasing to 78% and 58% with the addition of hydrochlorothiazide, respectively. Captopril caused a BP fall of 19/ 12 mmHg compared with 27/18 mmHg for perindopril, with 49% of both groups being controlled on monotherapy.4. Diuretic addition produced a greater antihypertensive effect with perindopril (75%) compared with 57% for captopril in achieving control. Perindopril caused a comparable fall in supine BP to the diuretic combination 27/19 mmHg and 31/ 18 mmHg, but the fall in erect systolic BP was significantly greater for the diuretic. At 3 months, 85% of the diuretic group and 78% of the perindopril group achieved the target BP. 5.A multicentre trial of 856 patients treated with perindopril(690 patients treated for 1 year or more) has shown that BP control is maintained in the long term with a low incidence of side-effects (7.9%) causing withdrawal from treatment. These studies demonstrate that perindopril compares favourably with standard first-line therapy for mild to moderate hypertension.

show abstract

Section: Long-term Perindopril Acceptabilitymentioning

confidence: 99%

Angiotensin‐converting Enzyme Inhibition as First‐line Treatment for Hypertension

Thurston

1992

Clin Exp Pharma Physio

View full text Add to dashboard Cite

show abstract

“…Generally, complaints of sleep difficulties and/or sedation occur more frequently when the pharmacotherapy regimen includes beta-blockers and alpha-2 receptor agonists, 11,12 although occasional sleep symptoms have also been reported with administration of other blood pressure-lowering drugs such as angiotensin-converting enzyme inhibitors 13 and calcium channel blockers.…”

mentioning

confidence: 99%

Portable Sleep Monitoring Systems: Broadening the Horizons

Covassin

Somers

2017

Journal of Clinical Sleep Medicine

View full text Add to dashboard Cite

show abstract

Clinical acceptability of ACE inhibitor therapy in mild to moderate hypertension, a comparison between perindopril and enalapril

Alcocer

Campos

Bahena³

et al. 1995

Cardiovasc Drug Ther

View full text Add to dashboard Cite

The aim of this 3-month double-blind study was to assess the antihypertensive effect and acceptability of perindopril in comparison with enalapril in patients with mild to moderate essential hypertension. After a 4-week placebo run-in period, 161 patients with supine diastolic blood pressure (DBP) between 95 and 115 mmHg were randomized to receive perindopril 4 mg or enalapril 10 mg once daily. If supine DBP was higher than 90 mmHg, treatment was adjusted monthly, first by doubling the dose and then by addition of hydrochlorothiazide 12.5 mg. After 3 months of active treatment the decrease in supine and standing blood pressures was statistically significant within both groups but was not statistically different between groups. The percentage of patients (65%) who achieved supine DBP of < or = 90 mmHg in the perindopril group was not significantly different from the enalapril group (73%). Monotherapy resulted in control of supine DBP in 56% of the perindopril group and 58% of the enalapril group; the addition of hydrochlorothiazide resulted in control of supine DBP in 6% and 15% respectively. The number of withdrawals for adverse events was statistically significant between groups (0 in the perindopril group and 7 in the enalapril group, p = 0.01). During active treatment the most frequently reported complaints were headaches and cough; there was not statistically difference between groups. Changes in laboratory parameters were minor and not significantly different between the two groups except for serum glucose, potassium, and triglyceride levels. In conclusion, there was no significance between perindopril and enalapril in terms of efficacy. Clinical acceptability seems to be better in the perindopril group.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Long-term acceptability of perindopril: European multicenter trial on 856 patients

Cited by 17 publications

References 17 publications

Angiotensin‐converting Enzyme Inhibition as First‐line Treatment for Hypertension

Angiotensin‐converting Enzyme Inhibition as First‐line Treatment for Hypertension

Portable Sleep Monitoring Systems: Broadening the Horizons

Clinical acceptability of ACE inhibitor therapy in mild to moderate hypertension, a comparison between perindopril and enalapril

Contact Info

Product

Resources

About